GLP1R and type 2 diabetes mellitus: The first report on direct effects of dual GLP-1/GIP receptor agonism on the kidneys comes from a prespecified exploratory analysis of the Tirzepatide Versus Insulin Glargine in Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4) study [32].